论文部分内容阅读
目的:探讨康艾注射液联合放化疗方案治疗对中晚期食管癌的临床效果。方法:67例中晚期食管癌患随机分为观察组34例和对照组33例。两组均采用放射治疗+化疗,观察组加用康艾注射液,40 mL,用5%葡葡糖或0.9%生理盐水250 mL稀释后静脉滴注,2次/d。疗程6周。观察两组疲乏状况,评价生活质量及毒副反应。结果:治疗后观察组疲乏程度明显轻于对照组(P<0.05);治疗后观察组生活质量评分为(57.54±4.77)分,优于对照组的(51.45±6.12)分(P<0.05);观察组出现Ⅲ度骨髓抑制7例(20.58%),低于对照组的15例(45.45%)(P<0.05);观察组Ⅲ度骨髓抑制出现时间(21.5±5.7)d,晚于对照组的(15.7±6.9)d(P<0.01);观察组有效率55.88%,对照组39.39%,两组差异不明显。结论:康艾注射液联合放化疗治疗中晚期食管癌患者能减轻患者的疲乏程度,减轻骨髓抑制,推迟Ⅲ度骨髓抑制发生的时间,提高了患者的生活质量。
Objective: To investigate the clinical effect of Kangai injection combined with radiotherapy and chemotherapy on advanced esophageal cancer. Methods: Sixty-seven patients with advanced esophageal cancer were randomly divided into observation group (34 cases) and control group (33 cases). The two groups were treated with radiotherapy and chemotherapy. The observation group was given Kangai injection, 40 mL, diluted with 250 mL of 5% glucose or 0.9% normal saline for 2 times / d. Treatment for 6 weeks. The fatigue of the two groups was observed to evaluate the quality of life and side effects. Results: After treatment, the fatigue of the observation group was significantly lower than that of the control group (P <0.05). After treatment, the quality of life of the observation group was (57.54 ± 4.77) points, which was significantly higher than that of the control group (51.45 ± 6.12) (P0.05) . The degree of myelosuppression in the observation group was 7 cases (20.58%), which was lower than 15 cases (45.45%) in the control group (P <0.05) (15.7 ± 6.9) d (P <0.01). The effective rate in the observation group was 55.88%, while that in the control group was 39.39%. There was no significant difference between the two groups. Conclusion: Kangai injection combined with chemoradiotherapy for patients with advanced esophageal cancer patients can reduce the degree of fatigue, reduce bone marrow suppression, delayed the occurrence of Ⅲ degree myelosuppression, and improve the quality of life of patients.